223 related articles for article (PubMed ID: 28415593)
21. The Fat1 cadherin is overexpressed and an independent prognostic factor for survival in paired diagnosis-relapse samples of precursor B-cell acute lymphoblastic leukemia.
de Bock CE; Ardjmand A; Molloy TJ; Bone SM; Johnstone D; Campbell DM; Shipman KL; Yeadon TM; Holst J; Spanevello MD; Nelmes G; Catchpoole DR; Lincz LF; Boyd AW; Burns GF; Thorne RF
Leukemia; 2012 May; 26(5):918-26. PubMed ID: 22116550
[TBL] [Abstract][Full Text] [Related]
22. The expression of CSRP2 encoding the LIM domain protein CRP2 is mediated by TGF-beta in smooth muscle and hepatic stellate cells.
Herrmann J; Borkham-Kamphorst E; Haas U; Van de Leur E; Fraga MF; Esteller M; Gressner AM; Weiskirchen R
Biochem Biophys Res Commun; 2006 Jul; 345(4):1526-35. PubMed ID: 16735029
[TBL] [Abstract][Full Text] [Related]
23. SNV and haplotype analysis reveals new CSRP1 variants associated with growth and carcass traits.
He H; Liu XL; Zhang HL; Yang J; Niu FB; Li ZX; Liu Y; Chen L
Gene; 2013 Jun; 522(2):206-13. PubMed ID: 23537997
[TBL] [Abstract][Full Text] [Related]
24. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
25. Minimal residual disease-based treatment is adequate for relapse-prone childhood acute lymphoblastic leukemia with an intrachromosomal amplification of chromosome 21: the experience of the ALL-BFM 2000 trial.
Attarbaschi A; Panzer-Grümayer R; Mann G; Möricke A; König M; Mecklenbräuker A; Teigler-Schlegel A; Bradtke J; Harbott J; Göhring G; Stanulla M; Schrappe M; Zimmermann M; Haas OA;
Klin Padiatr; 2014 Nov; 226(6-7):338-43. PubMed ID: 25431866
[TBL] [Abstract][Full Text] [Related]
26. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ
Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681
[TBL] [Abstract][Full Text] [Related]
27. Targeted disruption of the mouse Csrp2 gene encoding the cysteine- and glycine-rich LIM domain protein CRP2 result in subtle alteration of cardiac ultrastructure.
Sagave JF; Moser M; Ehler E; Weiskirchen S; Stoll D; Günther K; Büttner R; Weiskirchen R
BMC Dev Biol; 2008 Aug; 8():80. PubMed ID: 18713466
[TBL] [Abstract][Full Text] [Related]
28. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia.
Wuchter C; Leonid K; Ruppert V; Schrappe M; Büchner T; Schoch C; Haferlach T; Harbott J; Ratei R; Dörken B; Ludwig WD
Haematologica; 2000 Jul; 85(7):711-21. PubMed ID: 10897123
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of MSI2 predicts unfavorable outcome in adult B-acute lymphoblastic leukemia.
Aly RM; Ghazy HF
Int J Lab Hematol; 2015 Apr; 37(2):272-8. PubMed ID: 25090928
[TBL] [Abstract][Full Text] [Related]
30. The clinical impact of IKZF1 deletions in paediatric B-cell precursor acute lymphoblastic leukaemia is independent of minimal residual disease stratification in Nordic Society for Paediatric Haematology and Oncology treatment protocols used between 1992 and 2013.
Olsson L; Ivanov Öfverholm I; Norén-Nyström U; Zachariadis V; Nordlund J; Sjögren H; Golovleva I; Nordgren A; Paulsson K; Heyman M; Barbany G; Johansson B
Br J Haematol; 2015 Sep; 170(6):847-58. PubMed ID: 26018335
[TBL] [Abstract][Full Text] [Related]
31. Immunophenotypic Characterization of Cytogenetic Subgroups in Egyptian Pediatric Patients With B-Cell Acute Lymphoblastic Leukemia.
Adnan Awad S; Kamel MM; Ayoub MA; Kamel AM; Elnoshokaty EH; El Hifnawi N
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S19-S24.e1. PubMed ID: 27521317
[TBL] [Abstract][Full Text] [Related]
32. Increased neointima formation in cysteine-rich protein 2-deficient mice in response to vascular injury.
Wei J; Gorman TE; Liu X; Ith B; Tseng A; Chen Z; Simon DI; Layne MD; Yet SF
Circ Res; 2005 Dec; 97(12):1323-31. PubMed ID: 16269651
[TBL] [Abstract][Full Text] [Related]
33. Survivin and its prognostic significance in pediatric acute B-cell precursor lymphoblastic leukemia.
Troeger A; Siepermann M; Escherich G; Meisel R; Willers R; Gudowius S; Moritz T; Laws HJ; Hanenberg H; Goebel U; Janka-Schaub GE; Mahotka C; Dilloo D
Haematologica; 2007 Aug; 92(8):1043-50. PubMed ID: 17640858
[TBL] [Abstract][Full Text] [Related]
34. CD20 expression in B-cell precursor acute lymphoblastic leukemia is common in Mexican patients and lacks a prognostic value.
Solano-Genesta M; Tarín-Arzaga L; Velasco-Ruiz I; Lutz-Presno JA; González-Llano O; Mancías-Guerra C; Rodríguez-Romo L; Ruiz-Delgado GJ; Ruiz-Argüelles GJ; Jaime-Pérez JC; Gómez-Almaguer D
Hematology; 2012 Mar; 17(2):66-70. PubMed ID: 22664043
[TBL] [Abstract][Full Text] [Related]
35. Pediatric-Like Acute Lymphoblastic Leukemia Therapy in Adults With Lymphoblastic Lymphoma: The GRAALL-LYSA LL03 Study.
Lepretre S; Touzart A; Vermeulin T; Picquenot JM; Tanguy-Schmidt A; Salles G; Lamy T; Béné MC; Raffoux E; Huguet F; Chevallier P; Bologna S; Bouabdallah R; Benichou J; Brière J; Moreau A; Tallon-Simon V; Seris S; Graux C; Asnafi V; Ifrah N; Macintyre E; Dombret H
J Clin Oncol; 2016 Feb; 34(6):572-80. PubMed ID: 26644537
[TBL] [Abstract][Full Text] [Related]
36. A risk score including microdeletions improves relapse prediction for standard and medium risk precursor B-cell acute lymphoblastic leukaemia in children.
Sutton R; Venn NC; Law T; Boer JM; Trahair TN; Ng A; Den Boer ML; Dissanayake A; Giles JE; Dalzell P; Mayoh C; Barbaric D; Revesz T; Alvaro F; Pieters R; Haber M; Norris MD; Schrappe M; Dalla Pozza L; Marshall GM
Br J Haematol; 2018 Feb; 180(4):550-562. PubMed ID: 29194562
[TBL] [Abstract][Full Text] [Related]
37. Treatment of B-cell precursor acute lymphoblastic leukemia with the Galectin-1 inhibitor PTX008.
Paz H; Joo EJ; Chou CH; Fei F; Mayo KH; Abdel-Azim H; Ghazarian H; Groffen J; Heisterkamp N
J Exp Clin Cancer Res; 2018 Mar; 37(1):67. PubMed ID: 29580262
[TBL] [Abstract][Full Text] [Related]
38. Molecular detection of minimal residual disease is associated with early relapse in adult acute lymphoblastic leukemia.
Specchia G; Liso A; Pannunzio A; Albano F; Mestice A; Pastore D; Liso V
Haematologica; 2004 Oct; 89(10):1271-3. PubMed ID: 15477219
[TBL] [Abstract][Full Text] [Related]
39. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
[TBL] [Abstract][Full Text] [Related]
40. X-linked FHL1 as a novel therapeutic target for head and neck squamous cell carcinoma.
Cao W; Liu J; Xia R; Lin L; Wang X; Xiao M; Zhang C; Li J; Ji T; Chen W
Oncotarget; 2016 Mar; 7(12):14537-50. PubMed ID: 26908444
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
